Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) is a multinational healthcare company known for its diversified portfolio of pharmaceuticals, medical devices, and consumer health products. Founded in 1886, it has established itself as a leading player in healthcare, with a global presence and a reputation for innovation and quality in the industry.
Dividend History
Investors can expect a dividend payout of $1.30 per share, scheduled to be distributed in 18 days on December 9, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 9, 2025 | $1.30 | 2025-11-25 | 2025-11-25 |
| September 9, 2025 | $1.30 | 2025-08-26 | 2025-08-26 |
| June 10, 2025 | $1.30 | 2025-05-27 | 2025-05-27 |
| March 4, 2025 | $1.24 | 2025-02-18 | 2025-02-18 |
| December 10, 2024 | $1.24 | 2024-11-26 | 2024-11-26 |
Dividends Summary
- Johnson & Johnson has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 73 days ago, on September 9, 2025
- The highest dividend payed out to investors during this period was $1.30 per share
- The average dividend paid during this period was $0.74 per share.
Company News
The global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.
Johnson & Johnson reported strong Q3 results, beat Wall Street estimates, and announced the acquisition of Halda Therapeutics for $3.05 billion, focusing on expanding its oncology drug pipeline and offsetting competition in existing drug markets.
An analysis of five dividend aristocrat stocks that demonstrate consistent dividend growth, financial strength, and potential investment value across different sectors like healthcare, defense, consumer goods, and manufacturing.
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion, adding a clinical-stage prostate cancer therapy (HLD-0915) to its oncology pipeline. The transaction is expected to close within months and will slightly dilute earnings per share in 2026.
This week, J&J and Novartis reported strong Q2 earnings, while Roche's investigational oral weight loss drug showed positive results in an early-stage study. AbbVie also filed for approval of its drug Rinvoq for a new indication.
